A Study of Vemurafenib in Participants With Metastatic Melanoma
Status:
Completed
Trial end date:
2016-02-24
Target enrollment:
Participant gender:
Summary
This multi-center study evaluates the safety and efficacy of vemurafenib in participants with
BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV
(American Joint Committee on Cancer [AJCC]) metastatic melanoma.